New drug development Arnold Pharma's oral PD-L1 inhibitor AN4005 is approved by NMPA to start clinical trials

On December 13, 2021, Arnold Pharma announced that its original innovative drug oral PD-L1 inhibitor AN4005 has been approved by the National Medical Products Administration (NMPA) for drug clinical trials.
Center, Phase I study
.

 AN4005 is an orally active specific PD-L1 antagonist, showing strong anti-tumor activity in preclinical
.

AN4005 can effectively induce and stabilize the formation and dimerization of PD-L1 dimers, thereby effectively destroying the interaction between PD-1/PD-L1 proteins
.

Pre-clinical studies have shown that AN4005 has excellent in vitro activity and in vivo anti-tumor efficacy, as well as good druggability and safety
.

 More importantly, compared with the PD-(L)1 antibody that has been approved for marketing, AN4005 exhibits comparable in vitro and in vivo activities, and is strictly dependent on the immune system like other immune checkpoint inhibitors
.

As a small molecule drug for a variety of solid tumors, AN4005 has great potential in both single-agent therapy and combination medications
.

 In addition, compared with monoclonal antibodies, small molecule PD-(L)1 inhibitors have many potential advantages.
For example, oral administration can improve patient compliance; small molecules have a shorter half-life relative to antibodies, making immune-related Adverse reactions can be better controlled; the flexibility of small molecules can be more convenient and effective in the subsequent combination therapy
.

 Dr.
He Nanhai, head of Arnold Pharma's global research and development, said: As a small molecule PD-L1 inhibitor, AN4005 has shown good anti-tumor activity, and it will have a huge future in monotherapy and combination with other products of the company.
Potential
.

End reference materials: [1]https://mp.
weixin.
qq.
com/s/OXQ8HHRQJLrZE16nTmaxMA[2]https://mp.
weixin.
qq.
com/s/AM9V_WRYaI1riWUlH3Te2A Nature: "Athlete's blood" can resurrect sedentary mice with blood! Sub-Journal of Rewen Nature: The age of human death may be calculated, the greater the pressure, the faster the aging process.
Nature sub-published two articles in a row: Cancer cells "dormant" for several years, or the key factors that lead to cancer metastasis/recurrence.
Hot article "Nature" released "Top Ten People of 2021"! The chief designer of China's "Tianwen No.
1" and the tracker of the new crown virus variants are all on the list.
Be alert! Cell Reports: Potential star anti-cancer targets may promote cancer? Does this target have a future? Medical immunotherapy| Biosimilars| Vaccines| Drug resistance| Drug targets| Healthy life| Pharmaceutical company news| Drug inventory| Pharmaceutical technology| Basic research on side effects of drugs/ Translational medicine leukemia| Lung cancer| Gastric cancer| Colorectal cancer| Liver cancer| Breast Cancer | Pancreatic Cancer | Cardiovascular Diseases | Neurodegenerative Diseases | Intestinal Microbial Medical Devices / Biotechnology In Vitro Diagnosis | Medical Devices | Bio-Nano | 3D Printing | Gene Testing | Single Cell Sequencing | Gene Editing | Assisted Reproduction | Artificial Intelligence | Precision medicine policy anti-cancer drugs | 4+7 volume procurement | Consumables | Filing system | Registrant system | Healthy China | New edition of basic medicine catalog | AI medical equipment | Telemedicine | Same-share market with different rights/capital IPO | Financing | Cooperation | Funds | Hong Kong Stock Exchange | Science and Technology Innovation Board | Growth Enterprise Market | R & D Investment | Acquisitions | Market & Consumption